Krystal Biotech, Inc. (KRYS): Operating Income
$161.29M
Year ended 2025-12-31
| Period ended | Operating Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $161.29M | +145.3% | 2026-02-17, From 2025-01-01 |
| 2024-12-31 | $65.75M | n/m | 2026-02-17, From 2024-01-01 |
| 2023-12-31 | -$109.62M | n/m | 2026-02-17, From 2023-01-01 |
| 2022-12-31 | -$145.20M | n/m | 2025-02-19, From 2022-01-01 |
| 2021-12-31 | -$68.28M | n/m | 2024-02-26, From 2021-01-01 |
| 2020-12-31 | -$33.00M | n/m | 2023-02-27, From 2020-01-01 |
| 2019-12-31 | -$22.08M | n/m | 2021-03-01, From 2019-01-01 |
| 2018-12-31 | -$11.92M | n/m | 2020-03-10, From 2018-01-01 |
| 2017-12-31 | -$4.77M | n/m | 2018-03-12, From 2017-01-01 |
| 2016-12-31 | -$1.14M | n/a | 2018-03-12, From 2016-01-01 |
Operating Income at similar companies
| Company | Year ended | Operating Income | Change YoY |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | 2025-12-31 | $161.29M | +145.3% |
| Immunocore Holdings plc (IMCR) | 2025-12-31 | -$45.35M | n/m |
| Twist Bioscience Corp (TWST) | 2025-09-30 | -$136.26M | n/m |
| Tarsus Pharmaceuticals, Inc. (TARS) | 2025-12-31 | -$70.97M | n/m |
| ADMA Biologics, Inc. (ADMA) | 2025-12-31 | $191.44M | +37.7% |
| Adaptive Biotechnologies Corp (ADPT) | 2025-12-31 | -$57.12M | n/m |
| Vericel Corp (VCEL) | 2025-12-31 | $11.04M | +144.4% |
| Iovance Biotherapeutics, Inc. (IOVA) | 2025-12-31 | -$403.36M | n/m |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $18.07M | n/m |
Compare KRYS, IMCR, TWST, TARS side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗